OncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLC

OncoCyte (NASDAQ:OCX)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They presently have a $4.25 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 36.22% from the stock’s current price.

A number of other analysts have also commented on the company. Stephens reissued an “equal weight” rating and issued a $4.00 target price on shares of OncoCyte in a report on Wednesday, April 17th. StockNews.com started coverage on OncoCyte in a report on Sunday, August 4th. They issued a “sell” rating for the company. Finally, Benchmark reissued a “speculative buy” rating and issued a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.06.

OncoCyte Stock Up 1.3 %

NASDAQ:OCX traded up $0.04 during trading hours on Friday, reaching $3.12. 39,141 shares of the company traded hands, compared to its average volume of 42,557. The business’s 50-day moving average price is $2.97 and its two-hundred day moving average price is $2.91. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. On average, research analysts anticipate that OncoCyte will post -2.58 earnings per share for the current fiscal year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.